Novakhov, DeStefano, Simon, Davila, Bendett, Chang, Levenberg, Weprin, Paulin, Brown K
MLTSPNSR
Woerner
Amd §19.09, Ment Hyg L; amd §3309, Pub Health L
Relates to the availability of opioid reversal agents; requires the department of health to make available any formulation and dosage of opioid reversal agent approved by the federal food and drug administration.
STATE OF NEW YORK
________________________________________________________________________
265--A
2025-2026 Regular Sessions
IN ASSEMBLY(Prefiled)
January 8, 2025
___________
Introduced by M. of A. STECK, NOVAKHOV, DeSTEFANO, SIMON, DAVILA,
BENDETT, CHANG, LEVENBERG, WEPRIN, PAULIN, K. BROWN -- Multi-Sponsored
by -- M. of A. WOERNER -- read once and referred to the Committee on
Alcoholism and Drug Abuse -- committee discharged, bill amended,
ordered reprinted as amended and recommitted to said committee
AN ACT to amend the mental hygiene law and the public health law, in
relation to the availability of opioid reversal agents
The People of the State of New York, represented in Senate and Assem-bly, do enact as follows:
1 Section 1. Subdivision (l) of section 19.09 of the mental hygiene law,
2 as added by chapter 434 of the laws of 2021, is amended to read as
3 follows:
4 (l)(1) The office, in consultation with the department of health,
5 shall maintain on its website a publicly available directory of all
6 distributors of opioid [antagonists] reversal agents to the public,
7 including but not limited to, pharmacies, prevention programs and not-
8 for-profits. As used in this subdivision, the following terms shall have
9 the following meanings:
10 (i) "Opioid" means an opiate as defined in section thirty-three
11 hundred two of the public health law.
12 (ii) "Opioid [antagonist] reversal agents" means a federal food and
13 drug administration-approved drug that, when administered, negates or
14 neutralizes in whole or in part the pharmacological effects of an opioid
15 in the body. The [opioid antagonist shall be limited to naloxone or
16 other medications approved by the department of health for this purpose]
17 department of health shall make available any formulation and dosage of
18 opioid reversal agents that are approved by the federal food and drug
19 administration.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[] is old law to be omitted.
LBD00351-02-5
A. 265--A 2
1 (iii) "Purchaser" means any community organization, municipality,
2 pharmacy, medical facility, hospital, or any other entity, that accesses
3 opioid reversal drugs through the New York state standing order.
4 (2) The directory required by this subdivision shall include and be
5 searchable by the following information:
6 (i) addresses of each distributor of opioid [antagonists] reversal
7 agents;
8 (ii) contact information, such as phone numbers or email addresses,
9 for each distributor;
10 (iii) services offered by each distributor at each location if more
11 than one, as well as information providing which opioid [antagonists]
12 reversal agents are currently available at each distributor;
13 (iv) special populations served;
14 (v) insurance providers accepted;
15 (vi) hours of operation of each distributor;
16 (vii) contact information of opioid addiction prevention programs; and
17 (viii) any other information the commissioner deems necessary.
18 (3) The office may utilize an existing directory to satisfy the
19 requirements of this subdivision.
20 (4) The office shall allow for choice of any formulation and dosage of
21 opioid reversal agents that are approved by the federal food and drug
22 administration in the purchase, distribution or authorization to
23 prescribe or dispense such products. The department shall cover the cost
24 of any formulation and/or dosage of any federal food and drug adminis-
25 tration-approved nasal naloxone product. Any other product where the
26 cost exceeds that of highest-priced nasal naloxone product, that cost
27 overrun shall be borne by the purchaser.
28 § 2. Subparagraph (i) of paragraph (a) of subdivision 3 of section
29 3309 of the public health law, as amended by chapter 42 of the laws of
30 2014, is amended to read as follows:
31 (i) "Opioid [antagonist] reversal agents" means a drug approved by the
32 Food and Drug Administration that, when administered, negates or
33 neutralizes in whole or in part the pharmacological effects of an opioid
34 in the body. ["Opioid antagonist reversal agents" shall be limited to
35 naloxone and other medications approved by the department for such
36 purpose] The department shall make available any formulation and dosage
37 of opioid reversal agents that are approved by the federal Food and Drug
38 Administration.
39 § 3. Section 3309 of the public health law is amended by adding a new
40 subdivision 10 to read as follows:
41 10. Any purchase, distribution or authorization to prescribe pursuant
42 to this section by the commissioner shall allow for choice of any formu-
43 lation or dosage that is approved by the federal Food and Drug Adminis-
44 tration. The department shall cover the cost of any formulation and/or
45 dosage of any federal Food and Drug Administration-approved nasal nalox-
46 one product. Any other product where the cost exceeds that of highest-
47 priced nasal naloxone product, that cost overrun shall be borne by the
48 purchaser. Other products where the cost is lower than that of the
49 highest-priced nasal naloxone product shall be borne by the state.
50 § 4. This act shall take effect immediately.
